Filter
Period
Filter by
recent search
Showing: 1 – 05 of 30 Financial Results
31 July 2025
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
“Our half year results reflect continued strong momentum, with growth across all three therapeutic areas, particularly in our rare liver disease franchise, which is expanding rapidly and progressing well,” said David Loew, Chief Executive Officer, Ipsen. “Building on that performance,…
16 April 2025
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay.Tovorafenib regulatory submission to EMA2 for pediatric low-grade glioma.Confirmation of full-year 2025 financial guidance. PARIS,…
13 February 2025
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
PARIS, FRANCE, 13 February 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year 2024.
23 October 2024
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance
PARIS, FRANCE, 23 October 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its performance for the year to date and the third quarter of 2024.
25 July 2024
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
PARIS, FRANCE, 25 July 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the first half of 2024.
Your dedicated contacts
-
Khalid Deojee
Senior Manager, Investor Relations
